Literature DB >> 19960231

The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline.

Laurie E Gaspar1, Minesh P Mehta, Roy A Patchell, Stuart H Burri, Paula D Robinson, Rachel E Morris, Mario Ammirati, David W Andrews, Anthony L Asher, Charles S Cobbs, Douglas Kondziolka, Mark E Linskey, Jay S Loeffler, Michael McDermott, Tom Mikkelsen, Jeffrey J Olson, Nina A Paleologos, Timothy C Ryken, Steven N Kalkanis.   

Abstract

QUESTION: Should patients with newly-diagnosed metastatic brain tumors undergo open surgical resection versus whole brain radiation therapy (WBRT) and/or other treatment modalities such as radiosurgery, and in what clinical settings? TARGET POPULATION: These recommendations apply to adults with a newly diagnosed single brain metastasis amenable to surgical resection. RECOMMENDATIONS: Surgical resection plus WBRT versus surgical resection alone Level 1 Surgical resection followed by WBRT represents a superior treatment modality, in terms of improving tumor control at the original site of the metastasis and in the brain overall, when compared to surgical resection alone. Surgical resection plus WBRT versus SRS + or - WBRT Level 2 Surgical resection plus WBRT, versus stereotactic radiosurgery (SRS) plus WBRT, both represent effective treatment strategies, resulting in relatively equal survival rates. SRS has not been assessed from an evidence-based standpoint for larger lesions (>3 cm) or for those causing significant mass effect (>1 cm midline shift). Level 3 Underpowered class I evidence along with the preponderance of conflicting class II evidence suggests that SRS alone may provide equivalent functional and survival outcomes compared with resection + WBRT for patients with single brain metastases, so long as ready detection of distant site failure and salvage SRS are possible. Note The following question is fully addressed in the WBRT guideline paper within this series by Gaspar et al. Given that the recommendation resulting from the systematic review of the literature on this topic is also highly relevant to the discussion of the role of surgical resection in the management of brain metastases, this recommendation has been included below.

Entities:  

Mesh:

Year:  2009        PMID: 19960231      PMCID: PMC2808517          DOI: 10.1007/s11060-009-0060-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  32 in total

1.  Neurocognitive outcome in brain metastases patients treated with accelerated-fractionation vs. accelerated-hyperfractionated radiotherapy: an analysis from Radiation Therapy Oncology Group Study 91-04.

Authors:  W F Regine; C Scott; K Murray; W Curran
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-11-01       Impact factor: 7.038

Review 2.  The role of biologically effective dose (BED) in clinical oncology.

Authors:  B Jones; R G Dale; C Deehan; K I Hopkins; D A Morgan
Journal:  Clin Oncol (R Coll Radiol)       Date:  2001       Impact factor: 4.126

3.  A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104.

Authors:  K J Murray; C Scott; H M Greenberg; B Emami; M Seider; N L Vora; C Olson; A Whitton; B Movsas; W Curran
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-10-01       Impact factor: 7.038

4.  Radiation therapy for brain metastases from lung carcinoma. Prospective randomized trial according to the level of lactate dehydrogenase.

Authors:  M Chatani; Y Matayoshi; N Masaki; T Inoue
Journal:  Strahlenther Onkol       Date:  1994-03       Impact factor: 3.621

5.  A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis.

Authors:  A H Mintz; J Kestle; M P Rathbone; L Gaspar; H Hugenholtz; B Fisher; G Duncan; P Skingley; G Foster; M Levine
Journal:  Cancer       Date:  1996-10-01       Impact factor: 6.860

6.  Improved survival duration in patients with unresected solitary brain metastasis using accelerated hyperfractionated radiation therapy at total doses of 54.4 gray and greater. Results of Radiation Therapy Oncology Group 85-28.

Authors:  B E Epstein; C B Scott; W T Sause; M Rotman; P K Sneed; N A Janjan; L W Davis; H Selim; M Mohiuddin; T H Wasserman
Journal:  Cancer       Date:  1993-02-15       Impact factor: 6.860

7.  Whole-brain radiotherapy with 20 Gy in 5 fractions for brain metastases in patients with cancer of unknown primary (CUP).

Authors:  Dirk Rades; Guenther Bohlen; Radka Lohynska; Theo Veninga; Lukas J A Stalpers; Steven E Schild; Juergen Dunst
Journal:  Strahlenther Onkol       Date:  2007-11       Impact factor: 3.621

8.  Two radiation regimens and prognostic factors for brain metastases in nonsmall cell lung cancer patients.

Authors:  Dirk Rades; Steven E Schild; Radka Lohynska; Theo Veninga; Lukas J A Stalpers; Juergen Dunst
Journal:  Cancer       Date:  2007-09-01       Impact factor: 6.860

9.  Whole brain irradiation for metastases from lung carcinoma. A clinical investigation.

Authors:  M Chatani; T Teshima; K Hata; T Inoue; T Suzuki
Journal:  Acta Radiol Oncol       Date:  1985 Jul-Aug

10.  Comparison of short-course versus long-course whole-brain radiotherapy in the treatment of brain metastases.

Authors:  Dirk Rades; Guenther Bohlen; Juergen Dunst; Radka Lohynska; Theo Veninga; Lukas Stalpers; Steven E Schild; Jochen Dahm-Daphi
Journal:  Strahlenther Onkol       Date:  2008-01       Impact factor: 3.621

View more
  92 in total

Review 1.  Neurosurgical management of metastases in the central nervous system.

Authors:  Elizabeth B Claus
Journal:  Nat Rev Clin Oncol       Date:  2011-12-06       Impact factor: 66.675

2.  Expression profiling of angiogenesis-related genes in brain metastases of lung cancer and melanoma.

Authors:  Aysegül Ilhan-Mutlu; Christian Siehs; Anna Sophie Berghoff; Gerda Ricken; Georg Widhalm; Ludwig Wagner; Matthias Preusser
Journal:  Tumour Biol       Date:  2015-08-16

3.  Assessment of the molecular expression and structure of gangliosides in brain metastasis of lung adenocarcinoma by an advanced approach based on fully automated chip-nanoelectrospray mass spectrometry.

Authors:  Alina D Zamfir; Alina Serb; Željka Vukeli; Corina Flangea; Catalin Schiopu; Dragana Fabris; Svjetlana Kalanj-Bognar; Florina Capitan; Eugen Sisu
Journal:  J Am Soc Mass Spectrom       Date:  2011-10-15       Impact factor: 3.109

Review 4.  Surgical resection and whole brain radiation therapy versus whole brain radiation therapy alone for single brain metastases.

Authors:  M G Hart; R Grant; M Walker; H Dickinson
Journal:  Cochrane Database Syst Rev       Date:  2005-01-25

5.  The controversy surrounding the use of whole-brain radiotherapy in brain metastases patients.

Authors:  Minesh P Mehta
Journal:  Neuro Oncol       Date:  2015-07       Impact factor: 12.300

6.  Multisession gamma knife surgery for large brain metastases.

Authors:  Toshinori Hasegawa; Takenori Kato; Takashi Yamamoto; Hiroshi Iizuka; Tomohide Nishikawa; Hiroshi Ito; Naoki Kato
Journal:  J Neurooncol       Date:  2016-11-10       Impact factor: 4.130

7.  Effect of chemotherapy on survival after whole brain radiation therapy for brain metastases: a single-center retrospective analysis.

Authors:  Hiroshi Mayahara; Minako Sumi; Yoshinori Ito; Syuhei Sekii; Kana Takahashi; Kouji Inaba; Yuuki Kuroda; Naoya Murakami; Madoka Morota; Jun Itami
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-23       Impact factor: 4.553

Review 8.  Oligometastatic breast cancer: a shift from palliative to potentially curative treatment?

Authors:  Simona Di Lascio; Olivia Pagani
Journal:  Breast Care (Basel)       Date:  2014-02       Impact factor: 2.860

9.  Prognostic factors for outcomes after whole-brain irradiation of brain metastases from relatively radioresistant tumors: a retrospective analysis.

Authors:  Thekla Meyners; Christine Heisterkamp; Jan-Dirk Kueter; Theo Veninga; Lukas J A Stalpers; Steven E Schild; Dirk Rades
Journal:  BMC Cancer       Date:  2010-10-26       Impact factor: 4.430

Review 10.  Controversies in the Therapy of Brain Metastases: Shifting Paradigms in an Era of Effective Systemic Therapy and Longer-Term Survivorship.

Authors:  Colette J Shen; Michael Lim; Lawrence R Kleinberg
Journal:  Curr Treat Options Oncol       Date:  2016-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.